Unfolding narratives, shaping futures

We're always working to initiate change for patients

This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.

UroGen® profile

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

See our pipeline

Our leadership

See full leadership team

News releases

May 22, 2024

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

PRINCETON, N.J. --(BUSINESS WIRE)--May 22, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD

Read story

May 13, 2024

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024 ENVISION data expected to support completion of UGN-102 NDA in Q3 2024 Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8

Read story

May 7, 2024

UroGen Pharma to Participate at Upcoming Investor Conferences

– Citizens JMP Life Sciences Conference – – H.C. Wainwright 2 nd Annual BioConnect Conference – PRINCETON, N.J. --(BUSINESS WIRE)--May 7, 2024-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty

Read story

Events

May 28, 2024

TD Cowen Virtual Oncology Summit

Listen to webcast

May 13, 2024

UroGen Pharma Q1 2024 Earnings Call

Listen to webcast

Mar 14, 2024

UroGen Pharma Q4 2023 Earnings Call

Listen to webcast

Mar 4, 2024

TD Cowen 44th Annual Health Care Conference

Listen to webcast

Feb 13, 2024

Oppenheimer 34th Annual Healthcare Life Sciences Conference

Listen to webcast

Feb 8, 2024

Guggenheim 6th Annual Biotechnology Conference

Listen to webcast

Jan 18, 2024

2024 B Riley Healthcare Conference

Listen to webcast

Nov 14, 2023

UroGen Pharma Q3 2023 Earnings Call

Listen to webcast

Sep 26, 2023

2023 Cantor Fitzgerald Global Healthcare Conference

Listen to webcast

Sep 12, 2023

H.C. Wainwright 25th Annual Global Investment Conference

Listen to webcast
Connect with us
For more information about our products